ASP Isotopes (ASPI) Emerging Growth Conference77 summary

Company overview and strategy

• Focuses on producing stable isotopes for medical, semiconductor, and nuclear energy markets.

• Operates three manufacturing plants in Pretoria, South Africa, with plans to expand to Iceland.

• PET Labs supplies PET isotopes for nuclear medicine and is profitable; Quantum Leap Energy targets future nuclear fuels and is planned for a spin-out.

• Plans to build additional plants and start commercial production, with commissioning underway.

• Multiple customer agreements signed, with ongoing discussions for further deals.

Technology and production

• Utilizes two enrichment methods: ASP Process (stationary wall centrifuge) and Quantum Enrichment (laser-based).

• ASP Process enables efficient, modular, and scalable enrichment of both light and heavy isotopes.

• Quantum Enrichment achieves high selectivity, demonstrated with lithium isotopes, and is being applied to uranium enrichment.

• Three plants in South Africa: carbon-14, multi-isotope (initially silicon-28), and ytterbium-176, all in various stages of commissioning.

• Plans to leverage Iceland’s low-cost energy for future plants, starting with zinc-68.

Market opportunities and supply chain

• Global isotope market is large and growing, driven by demand in nuclear medicine and advanced semiconductors.

• Signed contracts for silicon-28 with major semiconductor and industrial gas companies; additional customer discussions ongoing.

• Ytterbium-176 plant targets supply shortages for radiopharmaceuticals; samples expected to reach customers in early next year.

• Carbon-14 plant operational, awaiting feedstock; multi-year agreement with Canadian customer valued at minimum $2.5 million annually.

• Plans to expand into the U.S. to help build a domestic supply chain, addressing current lack of domestic enrichment.